esmolol has been researched along with digoxin in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (26.67) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Das, G; Michelson, EL; Platia, EV; Porterfield, JK | 1 |
| Bateman, TM; Conklin, CM; Czer, LS; Gray, RJ; Matloff, JM | 1 |
| Bies, CM; Lowenthal, DT; Porter, RS; Saris, SD; Slegowski, MB; Staudacher, A | 1 |
| Achari, R; Laddu, AR; Lowenthal, DT; Matier, WL; Porter, RS; Turlapaty, P | 1 |
| Appunn, DO; Shettigar, UR; Toole, JG | 1 |
| Herbert, ME; Rutz, F; Votey, SR | 1 |
| Bolar-Softich, KL; Elam, K | 1 |
| Bauer, A; Donahue, JK; Heldman, AW; McDonald, AD; Miller, JM; Nasir, K; Peller, L; Rade, JJ | 1 |
2 review(s) available for esmolol and digoxin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Dilemmas in the acute pharmacologic treatment of uncontrolled atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium Channel Blockers; Digoxin; Diltiazem; Emergency Medical Services; Humans; Propanolamines | 1997 |
3 trial(s) available for esmolol and digoxin
| Article | Year |
|---|---|
Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atrial Fibrillation; Atrial Flutter; Blood Pressure; Clinical Trials as Topic; Digoxin; Female; Heart Rate; Humans; Male; Middle Aged; Multicenter Studies as Topic; Propanolamines; Random Allocation; Verapamil | 1989 |
Clinical pharmacology, pharmacodynamics and interactions with esmolol.
Topics: Adrenergic beta-Antagonists; Clinical Trials as Topic; Digoxin; Drug Interactions; Humans; Infusions, Parenteral; Kinetics; Male; Morphine; Propanolamines; Time Factors; Warfarin | 1985 |
Combined use of esmolol and digoxin in the acute treatment of atrial fibrillation or flutter.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Atrial Flutter; Digoxin; Drug Therapy, Combination; Heart Rate; Humans; Propanolamines; Time Factors | 1993 |
10 other study(ies) available for esmolol and digoxin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Esmolol: a new ultrashort-acting beta-adrenergic blocking agent for rapid control of heart rate in postoperative supraventricular tachyarrhythmias.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Blood Pressure; Cardiac Surgical Procedures; Digoxin; Dose-Response Relationship, Drug; Heart Rate; Humans; Hypotension; Infusions, Parenteral; Middle Aged; Postoperative Complications; Premedication; Propanolamines; Tachycardia | 1985 |
Esmolol-digoxin drug interaction.
Topics: Adolescent; Adrenergic beta-Antagonists; Chromatography, High Pressure Liquid; Digoxin; Drug Interactions; Half-Life; Humans; Male; Propanolamines | 1987 |
New treatment of atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Calcium Channel Blockers; Digoxin; Diltiazem; Drug Therapy, Combination; Emergency Medicine; Heart Failure; Humans; Propanolamines; Verapamil | 1996 |
Inhibitory G protein overexpression provides physiologically relevant heart rate control in persistent atrial fibrillation.
Topics: Acute Disease; Adenoviridae; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrioventricular Node; Cardiac Pacing, Artificial; Digoxin; Diltiazem; Gene Expression Regulation; Genetic Therapy; Genetic Vectors; GTP-Binding Protein alpha Subunit, Gi2; GTP-Binding Protein alpha Subunits, Gi-Go; Heart Failure; Heart Rate; Propanolamines; Proto-Oncogene Proteins; Recombinant Fusion Proteins; Stroke Volume; Sus scrofa; Ultrasonography | 2004 |